US FDA Signals Increased Enforcement Activity against Prescription Drug Advertising and Promotion
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration is increasingly issuing letters to companies alleging violations in promotional material for prescription drugs, say Gerald Masoudi and Stefanie Doebler.